The price-to-earnings ratio for Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is above average at 20.53x, Company’s 36-month beta value is 0.44.Analysts have differing opinions on the stock, with 9 analysts rating it as a “buy,” 9 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for JAZZ is 57.54M, and currently, short sellers hold a 7.33% ratio of that floaft. The average trading volume of JAZZ on February 26, 2025 was 611.19K shares.
JAZZ) stock’s latest price update
The stock price of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has jumped by 2.05 compared to previous close of 139.67. Despite this, the company has seen a gain of 5.62% in its stock price over the last five trading days. zacks.com reported 2025-02-26 that Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.
JAZZ’s Market Performance
Jazz Pharmaceuticals plc (JAZZ) has experienced a 5.62% rise in stock performance for the past week, with a 14.59% rise in the past month, and a 13.94% rise in the past quarter. The volatility ratio for the week is 2.31%, and the volatility levels for the past 30 days are at 2.64% for JAZZ. The simple moving average for the past 20 days is 9.61% for JAZZ’s stock, with a 23.75% simple moving average for the past 200 days.
Analysts’ Opinion of JAZZ
Many brokerage firms have already submitted their reports for JAZZ stocks, with Wells Fargo repeating the rating for JAZZ by listing it as a “Overweight.” The predicted price for JAZZ in the upcoming period, according to Wells Fargo is $170 based on the research report published on February 13, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see JAZZ reach a price target of $175, previously predicting the price at $140. The rating they have provided for JAZZ stocks is “Overweight” according to the report published on December 12th, 2024.
Goldman gave a rating of “Buy” to JAZZ, setting the target price at $169 in the report published on June 05th of the previous year.
JAZZ Trading at 13.39% from the 50-Day Moving Average
After a stumble in the market that brought JAZZ to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 1.44% of gains for the given period.
Volatility was left at 2.64%, however, over the last 30 days, the volatility rate increased by 2.31%, as shares surge +13.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.43% upper at present.
During the last 5 trading sessions, JAZZ rose by +4.14%, which changed the moving average for the period of 200-days by +26.96% in comparison to the 20-day moving average, which settled at $129.94. In addition, Jazz Pharmaceuticals plc saw 15.74% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JAZZ starting from COZADD BRUCE C, who sale 1,500 shares at the price of $122.31 back on Feb 03 ’25. After this action, COZADD BRUCE C now owns 439,744 shares of Jazz Pharmaceuticals plc, valued at $183,465 using the latest closing price.
COZADD BRUCE C, the Officer of Jazz Pharmaceuticals plc, proposed sale 1,500 shares at $122.31 during a trade that took place back on Feb 03 ’25, which means that COZADD BRUCE C is holding shares at $183,465 based on the most recent closing price.
Stock Fundamentals for JAZZ
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.85 for the gross margin
The net margin for Jazz Pharmaceuticals plc stands at 0.14. The total capital return value is set at 0.07. Equity return is now at value 14.31, with 4.79 for asset returns.
Based on Jazz Pharmaceuticals plc (JAZZ), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 16.65. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 5.36.
Currently, EBITDA for the company is 716.63 million with net debt to EBITDA at -1.88. When we switch over and look at the enterprise to sales, we see a ratio of 1.55. The receivables turnover for the company is 5.68for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.46.
Conclusion
In a nutshell, Jazz Pharmaceuticals plc (JAZZ) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
